Overview

Stem Cell Transplant for Hemoglobinopathy

Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This study tests the clinical outcomes of one of two preparative regimens (determined by available donor source) in patients with non-malignant hemoglobinopathies. The researchers hypothesize that these regimens will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease. Regimen A2 has replaced Regimen A in this study. Two patients were treated on Regimen A but did not have evidence of initial engraftment thus triggering the stopping rule for that arm of this study.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Collaborator:
National Marrow Donor Program
Treatments:
Alemtuzumab
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Lenograstim
Sargramostim
Vidarabine